Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation

Neuroendocrine Tumors Clinical Trial

— SCIROCCO  

Official title:

Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation A Prospective Interventional Trial of Patients With Neuro-endocrine Tumors With Carcinoid Syndrome Receiving Octreotide LAR

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04140409
• Other study ID #: SCIROCCO
• Status: Terminated
• Phase: Phase 4
• Start date: February 2, 2016
• Est. completion date: September 19, 2019

Study information

• Verified date: October 2019
• Source: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multi-centric prospective interventional study in which patients with a symptomatic GEP-NET will receive octreotide LAR every 2, 3 or 4 weeks. The basal dose and the dose adaptation will be left at the discretion of the investigator depending on the rate of symptom control. Dose increase up to doses of 60 mg octreotide every 4 weeks, or increase of frequency up to 30 mg every 2 weeks can be done to obtain control of carcinoid symptoms, defined by at least a 50% decrease of the mean number of bowel movements per day and the total number of flushes over 7 days AND a maximum frequency of less than 4 bowel movements a day. If only one symptom is present, analysis will be done for that symptom only: refer to table in statistical analysis The concentration of serum octreotide level will be realized with LCMS/MS following the method of Capron & Wallemacq. Each blood sample should be taken 4 times per year just before the next injection of Octreotide LAR.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 10
• Est. completion date: September 19, 2019
• Est. primary completion date: June 30, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent GEP NET Ki 67 = 10 %

• Histologically or cytologically confirmed GEP NET

• Appearance of carcinoid syndrome maximum 6 months before the inclusion

• Evaluable or measurable disease (RECIST 1.1) WHO ECOG performance status 0-2

• Positive somatostatin receptor scintigraphy

• >18 years

• Life expectancy of at least 12 weeks

Exclusion Criteria:

• Uncontrolled concurrent disease which prevents the adequate management and follow-up of the NET.

• Previous malignancy in the last past 3 years except malignancies estimated as completely cured.

• Current pregnancy or breast feeding

• Concomitant anti-tumoral treatment, except external beam radiotherapy

Related Conditions & MeSH terms

• Carcinoid Syndrome
• Carcinoid Tumor
• Malignant Carcinoid Syndrome
• Neuroendocrine Tumors
• Serotonin Syndrome
• Syndrome

Intervention

Drug:
• Sandostatin
All patients will be treated with octreotide LAR intramuscular injections at maximum doses of 60 mg every 4 weeks or a frequency up to 30 mg octreotide LAR each 2 weeks. Change of dose or frequency is left at the discretion of the investigator until symptom control is obtained.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment succes vs treatment failure	The primary endpoint is defined as follows: Treatment success: Symptom control is achieved within 2 years of treatment with octreotide LAR. Symptom control is defined as at least a 50% decrease of the mean number of bowel movements per day and the total number of flushes over 7 days AND a maximum frequency of less than 4 bowel movements a day.; Treatment failure: No symptom control is achieved within 2 years of treatment with octreotide LAR.; The response rate will be calculated as the number of patients with treatment success divided by the total number of included patients that received at least one injection of octreotide LAR.	2 years
Secondary	Symptoms	To describe the number of symptoms in correlation to the serum octreotide level, defined by a blood level test of octreotide.	2 years
Secondary	Rate of diarrhea and flushes	To describe the rate of diarrhea and flushing via a patient diary	2 years
Secondary	Impact of increased dose	To describe the impact of increased dose of octreotide LAR on the symptoms: bowel movements and flushing (via patient diary).	2 years
Secondary	Changes in Quality of life	To describe the effect of Octreotide LAR on Quality of Life, based on the change from baseline in the OLO-GINET21 scores	2 years
Secondary	Effect on tumor control	To describe the effect of Octreotide LAR on tumor control according to RECIST 1.1 criteria; •	2 years
Secondary	Toxicities	To describe the safety of octreotide (CTCAE grades)	2 years
Secondary	Correlation dose/frequency	To describe the correlation between the dose/frequency of octreotide LAR given and the serum octreotide level.	2 years